21 CFR 210.3 - Definitions

What it says

21 CFR 210.3 establishes the definitions used throughout Part 211, including terms such as batch, lot, component, drug product, in-process material, and quality control unit, providing the shared vocabulary that gives specific meaning to every other requirement in the cGMP regulations.

Paraphrased for plain-language clarity. Always verify against the current published regulation text.

What it means in practice

• Precise regulatory definitions matter in practice because they determine the actual scope of other requirements - what counts as a batch, for example, directly determines the scope of investigation and scope extension obligations under 211.192.
• Terms that sound intuitive in everyday use, such as component or in-process material, carry specific regulatory definitions that can differ meaningfully from casual industry usage.
• Misapplying a foundational definition can cascade into broader compliance gaps, since so many other Part 211 requirements are written in terms of these specific defined concepts.

What FDA inspectors look for

• Whether a site's internal procedures and terminology align with the regulatory definitions, or whether informal, drifted terminology has created ambiguity about scope.
• Whether personnel, when interviewed, demonstrate genuine understanding of what terms like batch or lot mean for scope-extension and investigation purposes, not just casual familiarity.
• Whether documentation consistently applies defined terms in a way that matches their regulatory meaning across different systems and departments.

Related regulations